MedEquities Realty Trust Inc (NYSE:MRT) – Cantor Fitzgerald lowered their FY2018 earnings estimates for MedEquities Realty Trust in a report issued on Tuesday, May 22nd, according to Zacks Investment Research. Cantor Fitzgerald analyst J. France now forecasts that the financial services provider will earn $1.19 per share for the year, down from their previous estimate of $1.21. Cantor Fitzgerald currently has a “Buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald also issued estimates for MedEquities Realty Trust’s FY2019 earnings at $1.26 EPS.
Several other brokerages also recently issued reports on MRT. JMP Securities set a $13.00 price objective on MedEquities Realty Trust and gave the stock a “buy” rating in a research note on Friday, May 11th. B. Riley set a $13.00 target price on MedEquities Realty Trust and gave the stock a “buy” rating in a research report on Thursday, February 22nd. ValuEngine raised MedEquities Realty Trust from a “hold” rating to a “buy” rating in a research report on Monday, March 19th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $11.00 target price (down from $12.00) on shares of MedEquities Realty Trust in a research report on Wednesday, May 23rd. Finally, KeyCorp dropped their target price on MedEquities Realty Trust from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Monday, April 16th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. MedEquities Realty Trust currently has an average rating of “Hold” and an average price target of $12.25.
MedEquities Realty Trust traded up $0.02, hitting $10.31, during mid-day trading on Wednesday, Marketbeat Ratings reports. The company’s stock had a trading volume of 95,600 shares, compared to its average volume of 153,437. The company has a market cap of $326.84 million, a P/E ratio of 9.03 and a beta of -0.12. MedEquities Realty Trust has a 52-week low of $9.67 and a 52-week high of $13.06.
MedEquities Realty Trust (NYSE:MRT) last announced its quarterly earnings data on Thursday, May 10th. The financial services provider reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.14). The business had revenue of $16.72 million during the quarter, compared to analysts’ expectations of $16.41 million. MedEquities Realty Trust had a return on equity of 6.17% and a net margin of 34.63%.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 5th. Stockholders of record on Tuesday, May 22nd were issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 8.15%. The ex-dividend date was Monday, May 21st. MedEquities Realty Trust’s dividend payout ratio is 73.68%.
In other news, Director Bluemountain Capital Managemen sold 17,674 shares of the stock in a transaction dated Friday, May 4th. The stock was sold at an average price of $10.16, for a total transaction of $179,567.84. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders have sold 363,688 shares of company stock worth $3,756,271. 3.00% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of MRT. LSV Asset Management acquired a new position in shares of MedEquities Realty Trust during the 4th quarter valued at about $103,000. MetLife Investment Advisors LLC acquired a new position in shares of MedEquities Realty Trust during the 4th quarter valued at about $120,000. Barclays PLC increased its holdings in shares of MedEquities Realty Trust by 252.2% during the 1st quarter. Barclays PLC now owns 16,016 shares of the financial services provider’s stock valued at $168,000 after acquiring an additional 11,469 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of MedEquities Realty Trust by 221.9% during the 1st quarter. JPMorgan Chase & Co. now owns 19,898 shares of the financial services provider’s stock valued at $210,000 after acquiring an additional 13,717 shares during the last quarter. Finally, UBS Group AG increased its holdings in shares of MedEquities Realty Trust by 52.3% during the 1st quarter. UBS Group AG now owns 23,234 shares of the financial services provider’s stock valued at $244,000 after acquiring an additional 7,978 shares during the last quarter. 93.53% of the stock is currently owned by institutional investors and hedge funds.
About MedEquities Realty Trust
MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company's management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.